Hemostasis in the post-COVID period

V. Gorodin, D. Moysova, I. I. Chuprov
{"title":"Hemostasis in the post-COVID period","authors":"V. Gorodin, D. Moysova, I. I. Chuprov","doi":"10.20953/1729-9225-2023-2-57-63","DOIUrl":null,"url":null,"abstract":"This review shows the current literature data on the delayed consequences of COVID-19 for the hemostasis. The pathogenesis, epidemiology, clinical manifestations, diagnostics, and possibilities of correction of hemostasis disorders are presented. In the context of declining mortality from COVID-19, the long-term multisystem consequences of the disease, which significantly affect the life quality oof convalescents are gradually becoming the main health problem of all states. The main mechanism for the occurrence of post-COVID syndrome is persistent inflammation, which is an important part of endotheliopathy. Most of the modern studies indicate a low incidence of VTE (0.8–1.6%) and arterial thrombosis (0.75%) in the post-COVID period. Laboratory data in the post-COVID period confirm endothelial dysfunction and the persisting prothrombotic phenotype of hemostasis disorder. The strategy of selective prolonged thromboprophylaxis of COVID-19 convalescents discharged from the hospital is justified, but the duration and criteria for the sufficiency of thromboprophylaxis are unknown. The tactics of endothelial protection are recognized as pathogenetically significant, but there is no reliable evidence base for the use of sulodexide in the post-COVID period. Key words: post-COVID syndrome, hemostasis, thrombosis, anticoagulants, sulodexide","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2023-2-57-63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

This review shows the current literature data on the delayed consequences of COVID-19 for the hemostasis. The pathogenesis, epidemiology, clinical manifestations, diagnostics, and possibilities of correction of hemostasis disorders are presented. In the context of declining mortality from COVID-19, the long-term multisystem consequences of the disease, which significantly affect the life quality oof convalescents are gradually becoming the main health problem of all states. The main mechanism for the occurrence of post-COVID syndrome is persistent inflammation, which is an important part of endotheliopathy. Most of the modern studies indicate a low incidence of VTE (0.8–1.6%) and arterial thrombosis (0.75%) in the post-COVID period. Laboratory data in the post-COVID period confirm endothelial dysfunction and the persisting prothrombotic phenotype of hemostasis disorder. The strategy of selective prolonged thromboprophylaxis of COVID-19 convalescents discharged from the hospital is justified, but the duration and criteria for the sufficiency of thromboprophylaxis are unknown. The tactics of endothelial protection are recognized as pathogenetically significant, but there is no reliable evidence base for the use of sulodexide in the post-COVID period. Key words: post-COVID syndrome, hemostasis, thrombosis, anticoagulants, sulodexide
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
covid后止血
本综述显示了目前关于COVID-19对止血的延迟后果的文献数据。介绍了止血障碍的发病机制、流行病学、临床表现、诊断和矫正的可能性。在COVID-19死亡率下降的背景下,疾病的长期多系统后果,严重影响康复者的生活质量,正逐渐成为各国的主要健康问题。持续炎症是新冠肺炎后综合征发生的主要机制,是内皮病变的重要组成部分。大多数现代研究表明,冠状病毒感染后静脉血栓形成(VTE)和动脉血栓形成(0.75%)的发生率较低(0.8-1.6%)。covid后的实验室数据证实了内皮功能障碍和持续的血栓前型止血障碍。COVID-19出院恢复期选择性延长血栓预防策略是合理的,但血栓预防的持续时间和充分性标准尚不清楚。内皮保护策略被认为具有病理学意义,但在covid后时期使用舒洛地德尚无可靠的证据基础。关键词:新冠肺炎后综合征,止血,血栓形成,抗凝剂,舒洛地特
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Infektsionnye Bolezni
Infektsionnye Bolezni Medicine-Infectious Diseases
CiteScore
1.30
自引率
0.00%
发文量
15
期刊介绍: The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.
期刊最新文献
Innovative approaches to treatment of human herpesvirus infections during the COVID-19 pandemic Atypical hemolytic uremic syndrome in a six-year-old child Viral infections as a cause or a trigger for the development of hemoblastosis? Antiviral therapy experience in patients with chronic hepatitis D and decompensated cirrhosis Treatment of patients with chronic HDV infection: routine clinical practice in the Moscow region
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1